Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
P. Sardari Nia, C. Colpaert, P. Vermeulen, E. Van Marck, P. Van Schil (Antwerp, Belgium). A novel biologic classification of non-small cell lung cancer. Eur Respir J 2005; 26: Suppl. 49, 182

Member's Comments

No comment yet.

Related content which might interest you: A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005 Lung cancer Source: Respipedia Article Year: 2018 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Staging of lung cancer Source: Eur Respir Mon; 2009: 44: 150–168 Year: 2009 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Age and stage at presentation in lung cancer Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Composite anatomical–clinical–molecular prognostic model in nonsmall cell lung cancer Source: Eur Respir J 2011; 37: 136-142 Year: 2011 ABCG2 is determinant to SN-38 resistance in non-small cell lung cancer Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 How to treat a T1-T3N0 non-small cell lung cancer (NSCLC) with isolated brain metastasis Source: International Congress 2015 – How to treat brain metastases Year: 2015 Trail receptors as prognostic factors in non-small cell lung cancer Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 New chemotherapeutic agents Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=259 Year: 2001 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 The impact of neuroendocrine differentiation in the prognosis of non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012